What this trial means for you
This study is recruiting now at 23 US sites. It's studying NNC0662-0419, Semaglutide, Placebo for diabetes mellitus, type 2.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion criteria * Male or female (sex at birth). * Age 18-75 years (both inclusive) at the time of signing the informed consent. * Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as assessed by central laboratory at screening. * Willingness to obtain a high weight loss (greater than \[\>\] 25% of weight at baseline). Exclusion criteria * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.
Study sites by state
California
- First Valley Medical Group — Lancaster · Recruiting now
- Torrance Clinical Research Institute, Inc. — Lomita · Recruiting now
- Ark Clinical Research — Long Beach · Recruiting now
- Pacific Clinical Studies — Los Alamitos · Recruiting now
- Wetlin Research Associates, Inc. — San Diego · Recruiting now
- Diablo Clinical Research, Inc. — Walnut Creek · Recruiting now
Florida
- Encore Medical Research LLC — Hollywood · Recruiting now
- Bioclinical Research Alliance — Miami · Recruiting now
- South Broward Research LLC — Miramar · Recruiting now
- West Orange Endocrinology — Ocoee · Opening soon
- Encore Medical Research of Weston — Weston · Recruiting now
Idaho
- Elite Clinical Trials — Blackfoot · Recruiting now
Illinois
- Cedar-Crosse Research Center — Chicago · Recruiting now
Massachusetts
- Brigham & Women's Hospital — Boston · Opening soon
Missouri
- Headlands Research — Springfield · Recruiting now
North Carolina
- PharmQuest — Greensboro · Recruiting now
- Piedmont Healthcare Statesville — Statesville · Recruiting now
Ohio
- Providence Center for Clinical Research — Dayton · Recruiting now
Tennessee
- CNS Healthcare — Memphis · Recruiting now
Texas
- University of Texas Southwestern Medical Center — Dallas · Recruiting now
- JCCT- Juno NW Houston — Houston · Recruiting now
- Consano Clinical Research, LLC — Shavano Park · Recruiting now
West Virginia
- Frontier Clinical Research - Kingwood — Kingwood · Opening soon
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)